US vaccine candidate Moderna has achieved 100 per cent efficacy against severe COVID-19 disease and has filed an application for “Emergency Use Authorisation” with the US Food and Drug Administration.
It follows Pfizer/BioNTech to become the second vaccine maker to request such an authorisation.
Loading...
Jill Margo is based in the Sydney office. Jill has won multiple prizes, including two Walkley Awards and is an adjunct associate professor at School of Clinical Medicine, Faculty of Medicine and Health, UNSW Sydney, Australia. Connect with Jill on Twitter. Email Jill at jmargo@afr.com
